Equity Overview
Price & Market Data
Price: $6.93
Daily Change: -$0.22 / 3.17%
Range: $6.87 - $7.13
Market Cap: $1,124,071,808
Volume: 5,179,609
Performance Metrics
1 Week: -6.85%
1 Month: 16.44%
3 Months: -13.14%
6 Months: -20.87%
1 Year: -58.51%
YTD: -13.68%
Company Details
Employees: 952
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.